Page last updated: 2024-08-21

quinazolines and inosine

quinazolines has been researched along with inosine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19902 (33.33)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Alfiero, R; Cocco, G; Padula, A; Rizzo, A; Strozzi, C; Tasini, MT; Urso, L1
Cocco, G; Sfrisi, C1
Bremer, HC; Elsner, P; Girolomoni, G; Herouy, Y; Idzko, M; Mockenhaupt, M; Norgauer, J; Panther, E; Sorichter, S; Windisch, W1
Cortés, D; Díaz-Cruz, A; Guinzberg, R; Piña, E; Riveros-Rosas, H; Villalobos-Molina, R1
Coe, IR; Naydenova, Z; Rose, JB1
Beesley, J; Gause, WC; Haskó, G; Lovászi, M; Németh, ZH; Pacher, P1

Reviews

2 review(s) available for quinazolines and inosine

ArticleYear
[Old and new positive inotropic drugs: problems and controversies].
    Minerva cardioangiologica, 1984, Volume: 32, Issue:11

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Glucagon; Glucosides; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Quinazolines; Xanthines

1984
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
    La Clinica terapeutica, 1984, Oct-31, Volume: 111, Issue:2

    Topics: Aminopyridines; Amrinone; Cardiac Glycosides; Cardiotonic Agents; Glucagon; Heart Failure; Histamine; Humans; Imidazoles; Inosine; Phosphodiesterase Inhibitors; Quinazolines; Sympathomimetics

1984

Other Studies

4 other study(ies) available for quinazolines and inosine

ArticleYear
Inosine stimulates chemotaxis, Ca2+-transients and actin polymerization in immature human dendritic cells via a pertussis toxin-sensitive mechanism independent of adenosine receptors.
    Journal of cellular physiology, 2004, Volume: 199, Issue:1

    Topics: Actins; Antigens, CD; Caffeine; Calcium; Cell Differentiation; Chemotaxis; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Inosine; Pertussis Toxin; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Triazoles; Xanthines

2004
Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors.
    American journal of physiology. Endocrinology and metabolism, 2006, Volume: 290, Issue:5

    Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Calcium; Cell Hypoxia; Cyclic AMP; Gluconeogenesis; Glucose; Glycogen Phosphorylase; Glycogenolysis; Hepatocytes; Inosine; Liver; Male; Phylogeny; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptor, Adenosine A3; Receptors, G-Protein-Coupled; Receptors, Purinergic; Receptors, Purinergic P1; Triazoles; Urea

2006
Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:6

    Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Cell Hypoxia; Cell Line; Cell Survival; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Inosine; Mice; Myocytes, Cardiac; Nucleoside Transport Proteins; Quinazolines; Receptor, Adenosine A1; Receptor, Adenosine A3; Thioinosine; Triazoles; Up-Regulation; Xanthines

2008
Inosine monophosphate and inosine differentially regulate endotoxemia and bacterial sepsis.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:11

    Topics: Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Disease Models, Animal; Endotoxemia; Inosine; Inosine Monophosphate; Interleukin-10; Male; Mice; Mice, Inbred C57BL; Pneumonia, Pneumococcal; Quinazolines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Signal Transduction; Streptococcus pneumoniae; Triazoles; Tumor Necrosis Factor-alpha

2021